Additionally, miR-126 could enhance EPC homing to thrombogenic and ischemic area by targeting PIK3R2 and CXCR4, which plays an important role in the therapeutic effect of EPCs on ischemic diseases [39, 49, 50]. Here, CXCR4 is linked to ischemic disease.